Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy

Breast Cancer Research and Treatment

Volumn 48, Issue 2, 1998, Pages 107-116

  Ellis, P A ^a   Smith, I E ^a   Detre, S ^a   Burton, S A ^a   Salter, J ^a   A'Hern, R ^a   Walsh, G ^a   Johnston, S R D ^a   Dowsett, M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Bcl 2 chemoresistance; Breast cancer; Immunostaining; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; PROTEIN BCL 2;

ADULT; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; ONCOGENE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0031960127     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005933815809     Document Type: Article

References (36)

1. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Internat Rev Cytol 68: 251-304, 1980
2. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121-139, 1992
3. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nat 348: 334-336, 1990
4. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukaemia cell line. Blood 81: 151-157, 1993
5. Kamesaki S, Kamesaki H, Jorgensen J, Tanizawa A, Pommier Y, Cossman J: Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase 2-induced DNA strand breaks and their repair. Cancer Res 53: 4251-4256, 1993
6. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Nunez G, Thompson CB: Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993
7. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74: 609-619, 1993
8. Reed JC: Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9: 451-474, 1995
9. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS: Overexpression of bcl-x sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55: 2507-2510, 1995
10. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D et al.: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547-552, 1995
11. Smith IE, Walsh G, Prendiville J, Johnston SRD, Ramage F, Robertshaw H, Sacks N, Ebbs S, McKinna JA, Baum M: High complete remissions with primary infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429, 1995
12. Bonadonna G, Valagussa P, Zucali R, Salvadori B: Primary chemotherapy in surgically resectable breast cancer. Ca Cancer J Clin 45: 227-243, 1995
13. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Brit J Cancer 67: 606-611, 1993
14. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baun M, Walton P, Sutcliffe E, Wakeling AE: Investigation of a new pure antioestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54: 408-414, 1994
15. Daidone MG, Silvestrini R, Luisi A, Mastore M, Benini E, Veneroni S, Brambilla C, Ferrari L, Greco M, Andreola S, Veronesi U: Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer 61: 301-305, 1995
16. Rasbridge, SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, Millis RR: The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70: 335-341, 1994
17. Wijsman JH, Jonker R, Keijzer R, Van De Velde CJH, Cornelisse CJ, Van Dierendonck JH: A new method to detect apoptosis in paraffin sections: In situ end-labelling of fragmented DNA. J Histochem Cytochem 41: 7-12, 1993
18. Hsu SM, Raine L, Fanger H: Use of the avidin-biotin-peroxidase complex (ABC) and unlabelled antibody (PAP) procedure. J Histochem Cytochem 29: 577-580, 1981
19. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K: Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 30A: 2068-2073, 1994
20. McClelland RA, Finlay P, Walker KJ, Nicholson D, Robertson JFR, Blamey RW: Automated quantitation of immunocytochemically localised oestrogen receptors in human breast cancer. Cancer Res 50: 3545-3550, 1990
21. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods ol clinical measurement. Lancet 1: 307-310, 1986
22. Evan GI, Wyllie AH, Gilbert CS et al.: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-129, 1992
23. Harris AL: What does BCL-2 mean in solid tumours - friend or foe? Ann Oncol 5: 388-390, 1994
24. Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsujimoto Y: Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature 374: 811-814, 1995
25. Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251, 1993
26. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in eaneer and chemoresistance. Curr Opinion Oncol 7: 541-546, 1995
27. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: bcl-2 in normal human breast and carcinoma: association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139, 1994
28. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI: Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994
29. Gasparini G, Barbareschi M, Doglioni C, Dalla Palma P, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, Pezella F, Harris AL: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node positive breast cancer. Clin Cancer Res 1: 189-198, 1995
30. Castle VP, Heidelberger KP, Bromberg J: Expression of the apoptosis suppressing protein BCL-2 in neuroblastoma is associated with unfavourable histology and n-myc amplification. Am J Pathol 143: 1543-1550, 1993
31. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J, Tu S, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992
32. Pezella F, Turley H, Kazu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY: bcl-2 protein in non-small-cell lung carcinoma. New Engl J Med 329: 690-694, 1993
33. Teixeira C, Reed JC, Pratt MAC: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995
34. Krajewski SBC, Franssila K, Krajewska M, Veli-Matti W, Nlskanen E, Nordling S, Reed JC: Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 4471-4478, 1995
35. Howell A, Harland RNL, Barnes DM, Baildam AD, Wilkinson MJS, Hayward E, Swindell R, Sellwood RA: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47: 300-304, 1987
36. Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331-3338, 1995